Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer

The benefit of combined CDK4/6 and anti-HER2 therapy in breast cancer is limited due to acquired resistance. Here, the authors perform single-cell analysis and show an immature myeloid cell population to infiltrate resistant tumors, and that combined cabozantinib and checkpoint therapy overcome this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qingfei Wang, Ian H. Guldner, Samantha M. Golomb, Longhua Sun, Jack A. Harris, Xin Lu, Siyuan Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c38f32d16a5646e1b6161ac0f8f636b7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c38f32d16a5646e1b6161ac0f8f636b7
record_format	dspace
spelling	oai:doaj.org-article:c38f32d16a5646e1b6161ac0f8f636b72021-12-02T17:31:52ZSingle-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer10.1038/s41467-019-11729-12041-1723https://doaj.org/article/c38f32d16a5646e1b6161ac0f8f636b72019-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11729-1https://doaj.org/toc/2041-1723The benefit of combined CDK4/6 and anti-HER2 therapy in breast cancer is limited due to acquired resistance. Here, the authors perform single-cell analysis and show an immature myeloid cell population to infiltrate resistant tumors, and that combined cabozantinib and checkpoint therapy overcome this resistance with a sustained efficacy.Qingfei WangIan H. GuldnerSamantha M. GolombLonghua SunJack A. HarrisXin LuSiyuan ZhangNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Qingfei Wang Ian H. Guldner Samantha M. Golomb Longhua Sun Jack A. Harris Xin Lu Siyuan Zhang Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
description	The benefit of combined CDK4/6 and anti-HER2 therapy in breast cancer is limited due to acquired resistance. Here, the authors perform single-cell analysis and show an immature myeloid cell population to infiltrate resistant tumors, and that combined cabozantinib and checkpoint therapy overcome this resistance with a sustained efficacy.
format	article
author	Qingfei Wang Ian H. Guldner Samantha M. Golomb Longhua Sun Jack A. Harris Xin Lu Siyuan Zhang
author_facet	Qingfei Wang Ian H. Guldner Samantha M. Golomb Longhua Sun Jack A. Harris Xin Lu Siyuan Zhang
author_sort	Qingfei Wang
title	Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
title_short	Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
title_full	Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
title_fullStr	Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
title_full_unstemmed	Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
title_sort	single-cell profiling guided combinatorial immunotherapy for fast-evolving cdk4/6 inhibitor-resistant her2-positive breast cancer
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/c38f32d16a5646e1b6161ac0f8f636b7
work_keys_str_mv	AT qingfeiwang singlecellprofilingguidedcombinatorialimmunotherapyforfastevolvingcdk46inhibitorresistanther2positivebreastcancer AT ianhguldner singlecellprofilingguidedcombinatorialimmunotherapyforfastevolvingcdk46inhibitorresistanther2positivebreastcancer AT samanthamgolomb singlecellprofilingguidedcombinatorialimmunotherapyforfastevolvingcdk46inhibitorresistanther2positivebreastcancer AT longhuasun singlecellprofilingguidedcombinatorialimmunotherapyforfastevolvingcdk46inhibitorresistanther2positivebreastcancer AT jackaharris singlecellprofilingguidedcombinatorialimmunotherapyforfastevolvingcdk46inhibitorresistanther2positivebreastcancer AT xinlu singlecellprofilingguidedcombinatorialimmunotherapyforfastevolvingcdk46inhibitorresistanther2positivebreastcancer AT siyuanzhang singlecellprofilingguidedcombinatorialimmunotherapyforfastevolvingcdk46inhibitorresistanther2positivebreastcancer
_version_	1718380454796591104

Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer

Ejemplares similares